Alpha Teknova, Inc.

Alpha Teknova, Inc.

TKNONYSE / NASDAQHealthcareSmall cap

$7.63-$0.18 (-2.3%)

Last close · Data as of Nov 20, 2026

Market cap
$291.1M
P/E
-16.9x
EV / EBITDA
-30.9x
Revenue
$40.5M
Net margin
-42.6%
ROCE
-17.7%

+72.4% over the last year

Alpha Teknova, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+3.2%
3M
+9.0%
6M
+106.2%
1Y
+72.4%
5Y
-69.5%

52-week range

Day change -$0.18 (-2.3%) from $7.81 to $7.63 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TKNO, bought on each weekday since 2021.

News & filings

What Alpha Teknova filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 17.3 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 45.2% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Read moreShow less

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Sector
Healthcare
Shares outstanding
53.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$291.1M
P/E
-16.9x
P/B
4.2x
EV / EBITDA
-30.9x
EV / Sales
7.7x
P/S
7.2x
52-week high
$9.33
52-week low
$1.99

Profitability

Operating margin
-41.9%
Net margin
-42.6%
EBITDA margin
-25.0%
ROE
-25.1%
ROCE
-17.7%
ROIC
-14.3%
ROA
-16.7%
Asset turnover
0.39

Growth

Revenue
$40.5M
Revenue growth, 1Y
7.4%
Revenue CAGR, 3Y
-0.7%
Net profit growth, 1Y
-35.5%
Free cash flow
-$9.8M

Solvency

Current ratio
4.58
Debt / Equity
0.41
Debt / Assets
0.27
CFO / Net profit
0.50
Cash / Market cap
2.0%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$40.5M
Cost of revenue$27.1M
Gross profit$13.4M
Operating expenses$30.4M
Research and development$2.2M
Selling, general and administrative$27.1M
Operating income-$17.0M
Interest and other-$220.0k
Pretax income-$17.2M
Tax and other$60.0k
Net income-$17.3M

Revenue and net profit

Revenue grew 7.4% in FY2025; net profit is the dashed line.

Alpha Teknova, Inc. revenue and net profit by fiscal year
Alpha Teknova, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$41.4M-$47.5M
FY2023$36.7M-$36.8M
FY2024$37.7M-$26.7M
FY2025$40.5M-$17.3M

Cash flows

FY2025: -$8.6M from operations, -$9.8M free after investment (dashed).

Alpha Teknova, Inc. operating and free cash flow by fiscal year
Alpha Teknova, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$27.4M-$55.5M
FY2023-$18.8M-$26.7M
FY2024-$12.4M-$13.5M
FY2025-$8.6M-$9.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$40.5M+7.4%1Y
EBITDA
-$10.1M
Net profit
-$17.3M
Cash from operations
-$8.6M
Free cash flow
-$9.8M
Revenue CAGR, 3Y
-0.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$40.5M-$10.1M-$17.3M-$9.8M-25.1%+7.4%-35.5%

Monthly returns

Month-by-month returns of TKNO across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$103.6M
Liabilities$34.8M
Equity$68.8M
Paid-in capital$204.6M
Retained earnings-$135.8M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TKNO highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Alpha Teknova, Inc. (this company)7.7x

Not shown (no positive earnings and no EV / Sales): DiaMedica Therapeutics Inc., Eledon Pharmaceuticals, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Alpha Teknova, Inc.TKNOthis company$291.1M-16.9x4.2x-25.1%-30.9x
DiaMedica Therapeutics Inc.DMAC$314.7M—5.6x-58.4%—
Electromed, Inc.ELMD$304.0M40.3x7.0x17.4%26.7x
Carlsmed, Inc.CARL$302.8M-10.2x3.1x-30.0%-8.4x
OraSure Technologies, Inc.OSUR$287.1M-4.2x0.8x-20.2%-1.7x
Niagen Bioscience, Inc.NAGE$278.8M16.0x3.6x22.7%13.8x
Quantum-Si incorporatedQSI$278.7M-2.8x1.3x-46.0%-2.8x
Eledon Pharmaceuticals, Inc.ELDN$277.9M-6.1x3.4x-56.3%-3.1x
Entrada Therapeutics, Inc.TRDA$271.7M-1.9x0.9x-47.0%-1.5x
Peer median—-2.8x3.2x-38.0%-1.7x

Year-to-date ROI

TKNO since 1 January, against earlier years.

Historical volatility

TKNO's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Alpha Teknova, Inc. operating margin by fiscal year
Alpha Teknova, Inc. operating margin by fiscal year
DateOperating margin
FY2022-69.7%
FY2023-85.1%
FY2024-69.3%
FY2025-41.9%
LineFY2025
Cost of revenueCost Of Revenue$27.1M
Gross profitGross Profit$13.4M
Operating expensesOperating Expense$30.4M
Research and developmentResearch And Development$2.2M
Depreciation and amortisationDepreciation And Amortization In Income Statement$1.1M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$1.1M
Amortization$1.1M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$1.1M
Total expensesTotal Expenses$57.5M
Pretax incomePretax Income-$17.2M

Learn while you research

Academy chapters picked for Alpha Teknova, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →